Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020227177 - METHODS OF ADMINISTERING CHIMERIC ANTIGEN RECEPTOR IMMUNOTHERAPY

Publication Number WO/2020/227177
Publication Date 12.11.2020
International Application No. PCT/US2020/031231
International Filing Date 03.05.2020
IPC
A61K 31/573 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopentahydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
57substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
573substituted in position 21, e.g. cortisone, dexamethasone, prednisone
A61K 38/34 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
33derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
34Melanocyte stimulating hormone , e.g. alpha- or beta-melanotropin
A61K 35/17 2015.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
17Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
Applicants
  • KITE PHARMA, INC. [US]/[US]
Inventors
  • JAIN, Rajul
  • VEZAN, Remus
Agents
  • MOUTA-BELLUM, Carla
Priority Data
62/843,19003.05.2019US
62/855,82831.05.2019US
62/868,26228.06.2019US
62/931,66906.11.2019US
62/944,90306.12.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHODS OF ADMINISTERING CHIMERIC ANTIGEN RECEPTOR IMMUNOTHERAPY
(FR) MÉTHODES D'ADMINISTRATION D'IMMUNOTHÉRAPIE PAR RÉCEPTEUR D'ANTIGÈNE CHIMÉRIQUE
Abstract
(EN)
The disclosure provides cells comprising CD19-directed chimeric antigen receptor (CAR) genetically modified autologous T cell immunotherapy for the treatment of, e.g., relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. Some aspects of the disclosure relate to methods of treatment and monitoring following infusion of T cell therapy provided herein.
(FR)
L'invention concerne une immunothérapie par lymphocytes T autologues génétiquement modifiés comprenant des cellules contenant le récepteur d'antigène chimérique (CAR) ciblé par le CD19 pour le traitement, par exemple, d'un lymphome à grandes cellules B récidivant ou réfractaire après au moins deux séances de thérapie systémique, notamment le lymphome diffus à grandes cellules B (LDGCB) non spécifié autrement, le lymphome médiastinal primitif à grandes cellules B, le lymphome à cellules B de haut grade et le LDGCB provenant d'un lymphome folliculaire. Certains aspects de l'invention concernent des méthodes de traitement et de surveillance suite à une perfusion du traitement par lymphocytes T selon l'invention.
Latest bibliographic data on file with the International Bureau